YD Bio CEO buys 12,700 shares at $3.85

YD Bio Ltd (YDES) reports that CEO and director Dr. Ethan Shen purchased 12,700 Ordinary Shares on September 14, 2026 in a transaction reported as a purchase in open market or private transactions at a weighted average price of $3.85 per share.

Rhea-AI Filing Summary

YD Bio Ltd (YDES) reports that CEO and director Dr. Ethan Shen purchased 12,700 Ordinary Shares on September 14, 2026 in a transaction reported as a purchase in open market or private transactions at a weighted average price of $3.85 per share. The trades occurred in multiple lots at prices between $3.67 and $3.97 per share. Following this transaction, Dr. Shen is reported to hold 11,258,331 Ordinary Shares directly and 43,120,858 Ordinary Shares indirectly through a trust structure for which he is the settlor, protector and sole beneficiary; no Rule 10b5-1 trading plan is indicated.

Insider Trade Summary

Net Buyer: 12,700 shares

Net Buy 2 txns

Insider Shen Ethan PhD

Role CEO

Bought 12,700 shs ($49K)

Type	Security	Shares	Price	Value
Purchase	Ordinary Shares F1	12,700	$3.85	$49K
holding	Ordinary Shares F2	--	--	--

Holdings After Transaction: Ordinary Shares — 11,258,331 shares (Direct); Ordinary Shares — 43,120,858 shares (Indirect, See Footnotes)

Footnotes (2)

1. F1. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $3.67 to $3.97, inclusive. The reporting person undertakes to provide to YD Bio Ltd (the "Company"), any security holder of the Company or the staff of the U.S. Securities and Exchange Commission (the "SEC"), upon request, full information regarding the number of Ordinary Shares purchased at each separate price within the range set forth above.
2. F2. The reported shares are held by YD Biopharma Holding Limited, which is wholly owned by E820N Assets Ltd. (BVI), which is wholly owned by The E820N Trust (the "Trust"). Dr. Shen is the settlor, protector and sole beneficiary of the Trust, and is the beneficial owner of such shares.

Key Figures

Shares purchased: 12,700 shares Weighted average purchase price: $3.85 per share Trade price range: $3.67–$3.97 per share +2 more

5 metrics

Shares purchased 12,700 shares Ordinary Shares acquired by CEO on September 14, 2026

Weighted average purchase price $3.85 per share Average price across multiple trades on September 14, 2026

Trade price range $3.67–$3.97 per share Range of prices for the purchased shares

Direct holdings after transaction 11,258,331 shares Ordinary Shares held directly by Dr. Shen following the purchase

Indirect holdings 43,120,858 shares Ordinary Shares held indirectly via YD Biopharma Holding Limited and The E820N Trust

Key Terms

weighted average price, beneficial owner, Ordinary Shares, settlor, +1 more

5 terms

weighted average price financial

"The price reported in Column 4 is a weighted average price."

Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.

beneficial owner financial

"Dr. Shen is the settlor, protector and sole beneficiary of the Trust, and is the beneficial owner of such shares."

A beneficial owner is the person who ultimately owns or controls a financial asset or property, even if their name isn't directly on official documents. Think of it like someone who secretly holds the keys to a safe deposit box—others may appear to have access, but the true owner is the one who benefits from what's inside. Identifying beneficial owners helps ensure transparency and prevent illegal activities like money laundering or fraud.

Ordinary Shares financial

"The reported shares are held by YD Biopharma Holding Limited, ... number of Ordinary Shares purchased at each separate price"

Ordinary shares are a type of ownership stake in a company, giving shareholders a right to participate in the company’s profits and decision-making through voting. They are similar to owning a piece of a business, and their value can rise or fall based on the company's performance. Investors buy ordinary shares to potentially earn dividends and benefit from the company's growth over time.

settlor other

"Dr. Shen is the settlor, protector and sole beneficiary of the Trust"

protector other

"Dr. Shen is the settlor, protector and sole beneficiary of the Trust"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did YDES report for CEO Ethan Shen?

YD Bio Ltd reported that CEO and director Dr. Ethan Shen purchased 12,700 Ordinary Shares on September 14, 2026, in a transaction reported as a purchase in open market or private transactions at a weighted average price of $3.85 per share.

At what price did the YDES CEO buy the shares?

Dr. Ethan Shen’s reported purchase of 12,700 Ordinary Shares had a weighted average price of $3.85 per share. The Form 4 states the trades were executed in multiple transactions at prices ranging from $3.67 to $3.97 per share, inclusive.

How many YDES shares does the CEO hold directly after this transaction?

After the September 14, 2026 purchase, Dr. Ethan Shen is reported to hold 11,258,331 Ordinary Shares directly. This figure is disclosed as the total number of directly owned shares following the reported transaction.

What is the indirect YDES share ownership reported for the CEO?

The Form 4 reports 43,120,858 Ordinary Shares held indirectly through YD Biopharma Holding Limited, owned through intermediate entities by The E820N Trust, for which Dr. Shen is the settlor, protector and sole beneficiary, making him the beneficial owner of those shares.

Was the YDES CEO’s share purchase under a Rule 10b5-1 trading plan?

The filing indicates no Rule 10b5-1 trading plan for the reported transactions. The Rule 10b5-1 checkbox is not affirmed, and the footnotes do not state that the trades were made pursuant to any pre-arranged trading plan.

What type of security did the YDES insider acquire?

The reported transaction involves Ordinary Shares of YD Bio Ltd. The Form 4 lists these as non-derivative securities, meaning they are the company’s common equity rather than options, warrants, or other derivative instruments.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 09/16/2026 - 04:02 PM Accepted by SEC EDGAR 09/16/2026 - 04:01 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Shen Ethan PhD

(Last) (First) (Middle)

C/O YD BIO LIMITED

12F., NO. 3, XINGNAN ST., NANGANG DIST.

(Street)

TAIPEI 115001

(City) (State) (Zip)

TAIWAN

(Country)

2. Issuer Name and Ticker or Trading Symbol
YD Bio Ltd [ YDES ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	CEO

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
09/14/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Ordinary Shares	09/14/2026		P		12,700	A	$3.85(1)	11,258,331	D
Ordinary Shares								43,120,858	I	See Footnotes(2)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $3.67 to $3.97, inclusive. The reporting person undertakes to provide to YD Bio Ltd (the "Company"), any security holder of the Company or the staff of the U.S. Securities and Exchange Commission (the "SEC"), upon request, full information regarding the number of Ordinary Shares purchased at each separate price within the range set forth above.

2. The reported shares are held by YD Biopharma Holding Limited, which is wholly owned by E820N Assets Ltd. (BVI), which is wholly owned by The E820N Trust (the "Trust"). Dr. Shen is the settlor, protector and sole beneficiary of the Trust, and is the beneficial owner of such shares.

	/s/ Ethan Shen	09/16/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)